Beatrice L. Brown joins Ethics Talk to discuss her article, coauthored with Dr Aaron S Kesselheim: "How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices?"
Gail Geller, ScD, MHS and Paul A. Watkins, MD, PhD
Six cohorts of first-year medical students have been shown to have negative attitudes about obesity that are consistent over time. Attitudes can be improved, however, by using popular media and an ethics framework to discuss personal experiences and beliefs about obesity.
AMA J Ethics. 2018;20(10):E948-959. doi:
10.1001/amajethics.2018.948.
Elizabeth Boskey, PhD, MPH, MSSW, Amir Taghinia, MD, and Oren Ganor, MD
Training should be implemented to respond to clinical staff members’ concerns about trans patients occupying sex-segregated spaces and to help mitigate anti-trans bias.
AMA J Ethics. 2018;20(11):E1067-1074. doi:
10.1001/amajethics.2018.1067.
Vegan patients screened for vitamin and mineral deficiencies might benefit from supplements, but physicians are obliged to discuss lack of regulation in the supplement industry and possible risks.
AMA J Ethics. 2018;20(11):E1025-1032. doi:
10.1001/amajethics.2018.1025.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.